A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept

2016/02/26 by Carlo Alviggi, Claus Y. Andersen, Claus Yding Andersen +12 · 28 citations
Medicine · #Ovarian function and disorders #Reproductive Biology and Fertility #Ovarian cancer diagnosis and treatment

paper · doi:10.1016/j.fertnstert.2016.02.005

Cited by

• Reduced FSH and LH action: implications for medically assisted reproduction
• Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons
• Transcriptomic landscape of cumulus cells from patients <38 years old with a history of poor ovarian response (POR) treated with platelet-rich plasma (PRP)
• The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. [europepmc]
• Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back. [europepmc]
• Individualized controlled ovarian stimulation in expected poor-responders: an update. [europepmc]
• Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. [europepmc]
• Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. [europepmc]
• Impact of Maternal Age on Oocyte and Embryo Competence. [europepmc]
• Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why. [europepmc]
• Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker-The Follicle-To-Oocyte (FOI) Index. [europepmc]
• The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. [europepmc]
• Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. [europepmc]
• A Novel Predictive Model to Estimate the Number of Mature Oocytes Required for Obtaining at Least One Euploid Blastocyst for Transfer in Couples Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection: The ART Calculator. [europepmc]
• Cumulative live birth rates in low-prognosis women. [europepmc]
• Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. [europepmc]
• Management of Women With an Unexpected Low Ovarian Response to Gonadotropin. [europepmc]
• Management Strategies for POSEIDON Groups 3 and 4. [europepmc]
• The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. [europepmc]
• Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. [europepmc]
• COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management. [europepmc]
• Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. [europepmc]
• Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. [europepmc]
• Reduced FSH and LH action: implications for medically assisted reproduction. [europepmc]
• Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies. [europepmc]
• Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. [europepmc]
• Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). [europepmc]
• Endometriosis and IVF treatment outcomes: unpacking the process. [europepmc]